Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xalacom vs Xalatan in Japanese patients with POAG or OH
NCT00383019Phase 3Completed
- Sponsor
- Viatris
- Start
- Nov 2006
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of timolol in primary open-angle glaucoma (POAG) and ocular hypertension (2 arms), sponsored by Viatris. Primary endpoint: Change of Intraocular Pressure From Baseline at 8 weeks. Started Nov 2006; status: completed.
02
Drugs
timolol
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT00383019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00383019.